Additional genetic risk factor for death in children with acute lymphoblastic leukemia: A common polymorphism of the MTHFR gene

Pediatric Blood and Cancer

Volumn 52, Issue 3, 2009, Pages 364-368

  Pietrzyk, Jacek J ^a   Bik Multanowski, Miroslaw ^a   Balwierz, Walentyna ^a   Skoczen, Szymon ^a   Wojcik, Dorota ^b   Chybicka, Alicja ^b   Sikorska Fic, Barbara ^c   Matysiak, Michal ^c   Szczepanski, Tomasz ^d   Sonta Jakimczyk, Danuta ^d   Ploszynska, Anna ^e   Balcerska, Anna ^e   Mycko, Katarzyna ^f   Bodalski, Jerzy ^f   Krawczuk Rybak, Maryna ^g   Kowalczyk, Jerzy ^h   Koltan, Andrzej ⁱ   Sobol, Grazyna ^d   Derwich, Katarzyna ^j   Kwinta, Przemko ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^h MEDICAL UNIVERSITY OF LUBLIN   (Poland)

ⁱ NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^j POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

more..

Author keywords

DNA methylation; Drug metabolism; Homocysteine; Mortality; Pharmacogenetics

Indexed keywords

BIOLOGICAL MARKER; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; MALE; PRIORITY JOURNAL; RISK FACTOR; ENZYMOLOGY; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MORTALITY; PRESCHOOL CHILD;

5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; MALE; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 58949100713     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21815     Document Type: Article

References (18)

1. Rubnitz JE, Pui C-H. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev 2003;29:31-44.
2. Krajinovic M, Labuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002;8:802-810.
3. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymi-dylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002;359:1033-1034.
4. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
5. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001;1:99-108.
6. Schrappe M,ReiterA,Zimmermann M,et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000;14:2205-2222.
7. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathio- prine and mercaptopurine intolerance. Ann Intern Med 1997;126: 608-614.
8. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
9. Chen C-L, Liu Q, Pui C-H, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukaemia. Blood 1997;89:1701-1707.
10. WilsonMH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 2000;14:791-796.
11. SkibolaCF, Smith MT, Hubbard A, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002;99:3786-3791.
12. Szczeklik A, Sanak M, Jankowski M, et al. Mutation A1298C of methylenetetrahydrofolate reductase: A risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet 2001;101:36-39.
13. Thirumaran RK, Gast A, Flohr T, et al. MTHFR genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Blood 2005;106:2590-2591.
14. Chatzidakis K, Goulas A, Athanassiadou-Piperopoulou F, et al. Methylenetetrahydrofolate reductase C677T polymorphism: Association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in Greekpatients. Pediatr Blood Cancer 2006;47:147-151.
15. Schnakenberg E, Mehles A, Cario G, et al. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet 2005;6:23.
16. Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005;65:2482-2487.
17. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004;4:66-72.
18. Harmon DL, Woodside JWG, Yarnell D, et al. The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q J Med 1996;89:571-577.